Eli Lilly and Co., of Indianapolis, said results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376) found that combination therapy was more effective in removing clumps of amyloid-beta protein in the brain use of one therapy.